Assyro AI

Orange Book product · Brand (NDA)

ORGOVYX

RELUGOLIX

Brand (NDA)NDA 214621RX SUMITOMO PHARMA AM

At a glance

Dec 18, 2020

Approved

Brand (NDA)

Application

Not listed

TE code

12

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Dec 18, 2020

    5 yr 7 mo ago

  2. Patent 8058280 expires

    Listed drug substance patent expiration.

    Jan 28, 2026

    5 mo ago

  3. Today

  4. Patent 7300935 expires

    Listed drug substance patent expiration.

    Jan 28, 2029

    in 2 yr 8 mo

  5. Patent 11795178 expires

    Listed drug substance patent expiration.

    Sep 27, 2033

    in 7 yr 5 mo

  6. Patent 12325714 expires

    Listed drug substance patent expiration.

    Sep 27, 2033

    in 7 yr 5 mo

  7. Patent 10350170 expires

    Listed drug product patent expiration.

    Feb 25, 2036

    in 9 yr 10 mo

  8. Patent 10449191 expires

    Listed method-of-use patent (U-3020) expiration.

    Sep 29, 2037

    in 11 yr 5 mo

  9. Patent 10786501 expires

    Listed method-of-use patent (U-3020) expiration.

    Sep 29, 2037

    in 11 yr 5 mo

  10. Patent 11583526 expires

    Listed method-of-use patent (U-3020) expiration.

    Sep 29, 2037

    in 11 yr 5 mo

  11. Patent 12097198 expires

    Listed method-of-use patent (U-3020) expiration.

    Sep 29, 2037

    in 11 yr 5 mo

  12. Patent 12144809 expires

    Listed method-of-use patent (U-4035) expiration.

    Sep 29, 2037

    in 11 yr 5 mo

  13. Patent 12336990 expires

    Listed method-of-use patent (U-3020) expiration.

    Sep 29, 2037

    in 11 yr 5 mo

  14. Patent 12629370 expires

    Listed method-of-use patent (U-3020) expiration.

    Sep 29, 2037

    in 11 yr 5 mo

Pharmaceutical detail

Active ingredient

RELUGOLIX

Strength

120MG

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 214621

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (12)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8058280Jan 28, 20265 mo ago
SubstanceProduct
7300935Jan 28, 2029in 2 yr 8 mo
Substance
11795178Sep 27, 2033in 7 yr 5 mo
SubstanceProduct
12325714Sep 27, 2033in 7 yr 5 mo
SubstanceProduct
10350170Feb 25, 2036in 9 yr 10 mo
Product
10449191Sep 29, 2037in 11 yr 5 mo
U-3020
10786501Sep 29, 2037in 11 yr 5 mo
U-3020
11583526Sep 29, 2037in 11 yr 5 mo
U-3020
12097198Sep 29, 2037in 11 yr 5 mo
U-3020
12144809Sep 29, 2037in 11 yr 5 mo
U-4035
12336990Sep 29, 2037in 11 yr 5 mo
U-3020
12629370Sep 29, 2037in 11 yr 5 mo
U-3020
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.